Description
Join G1 Therapeutics, Inc., a company focused on next-generation cancer therapies, as they review the current management of chemotherapy-induced myelosuppression (CIM). This presentation will highlight a new therapeutic approach to proactively help protect hematopoietic stem and progenitor cells in the bone marrow from chemotherapy-induced damage. Led by Tajuana Bradley, the session will outline the burden and current treatment landscape of CIM and present important information about a novel treatment. Mechanism of action, safety and efficacy data, and dosing and administration information will be discussed.
Speaker(s):
